Citadel Advisors
ATRA icon

Citadel Advisors’s Atara Biotherapeutics ATRA Stock Holding History

Citadel Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-520
Closed -$4.42K – 14213
2024
Q2 		$4.42K Sell
520
-216
-29% -$3.25K ﹤0.01% 13485
2024
Q1 		$12.8K Buy
736
+356
+94% +$6.32K ﹤0.01% 13344
2023
Q4 		$4.87K Sell
380
-30,544
-99% -$712K ﹤0.01% 13476
2023
Q3 		$1.14M Buy
30,924
+192
+0.6% +$8.55K ﹤0.01% 6292
2023
Q2 		$1.24M Sell
30,732
-656
-2% -$37.1K ﹤0.01% 6023
2023
Q1 		$2.28M Sell
31,388
-696
-2% -$67.5K ﹤0.01% 5117
2022
Q4 		$2.63M Buy
32,084
+31,580
+6,266% +$3.29M ﹤0.01% 4977
2022
Q3 		$48K Sell
504
-128
-20% -$14.4K ﹤0.01% 11657
2022
Q2 		$123K Sell
632
-220
-26% -$35.9K ﹤0.01% 11183
2022
Q1 		$198K Sell
852
-540
-39% -$172K ﹤0.01% 11554
2021
Q4 		$548K Buy
1,392
+764
+122% +$322K ﹤0.01% 9472
2021
Q3 		$281K Sell
628
-296
-32% -$106K ﹤0.01% 11187
2021
Q2 		$359K Sell
924
-1,692
-65% -$604K ﹤0.01% 10830
2021
Q1 		$939K Buy
2,616
+1,372
+110% +$606K ﹤0.01% 8286
2020
Q4 		$610K Sell
1,244
-136
-10% -$62.8K ﹤0.01% 7780
2020
Q3 		$447K Sell
1,380
-32
-2% -$10.9K ﹤0.01% 7490
2020
Q2 		$514K Buy
1,412
+468
+50% +$118K ﹤0.01% 7019
2020
Q1 		$201K Buy
944
+460
+95% +$146K ﹤0.01% 8002
2019
Q4 		$199K Buy
484
+28
+6% +$9.65K ﹤0.01% 8195
2019
Q3 		$161K Buy
456
+16
+4% +$5.97K ﹤0.01% 8265
2019
Q2 		$221K Sell
440
-1,624
-79% -$1.15M ﹤0.01% 8042
2019
Q1 		$2.05M Buy
+2,064
New +$1.92M ﹤0.01% 4418
2018
Q4 		– Sell
-644
Closed -$666K – 9076
2018
Q3 		$666K Buy
644
+136
+27% +$133K ﹤0.01% 6232
2018
Q2 		$467K Sell
508
-320
-39% -$344K ﹤0.01% 6480
2018
Q1 		$807K Buy
+828
New +$755K ﹤0.01% 5130

Other funds holding ATRA

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's ATRA Position: Q1 2026 in Review

Citadel Advisors sold out of Atara Biotherapeutics (ATRA) in Q1 2026, closing a stake of 15,577 shares — an estimated $282K sold.

Citadel Advisors first reported a position in ATRA in Q3 2015 and held it in 31 quarters. The position peaked at $9.08M in Q3 2019. 33 funds tracked by Wall St. Rank hold ATRA as of Q1 2026.

  • Citadel Advisors reported no remaining Atara Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 15,577 Atara Biotherapeutics shares in Q1 2026, an estimated $282K.
  • Citadel Advisors first reported a position in Atara Biotherapeutics in Q3 2015 and held it in 31 quarters.
  • Citadel Advisors's Atara Biotherapeutics position peaked at $9.08M in Q3 2019.
  • 33 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.